HIV proteinase as a target for drug action

Review

. 1989 Aug;10(8):305-7.

doi: 10.1016/0165-6147(89)90060-6.

Review

M I Johnston et al. Trends Pharmacol Sci. 1989 Aug.

. 1989 Aug;10(8):305-7.

doi: 10.1016/0165-6147(89)90060-6.

No abstract available

Similar articles

[The HIV proteinase--a target for antiviral agents].
Grinde B, Jonassen TO. Grinde B, et al. Tidsskr Nor Laegeforen. 1996 Oct 10;116(24):2908-11. Tidsskr Nor Laegeforen. 1996. PMID: 8975409 Review. Norwegian.
[Therapeutic drugs--rarely causal therapy].
Uhl D. Uhl D. Med Monatsschr Pharm. 1990 May;13(5):129. Med Monatsschr Pharm. 1990. PMID: 2192241 German. No abstract available.
Characterisation of drug resistant retroviral proteinase mutants.
Good VM, Anderson MM, Baker JJ, Moloudi A, James CH, Wilderspin AF. Good VM, et al. Biochem Soc Trans. 1997 Nov;25(4):S633. doi: 10.1042/bst025s633. Biochem Soc Trans. 1997. PMID: 9450061 No abstract available.
The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.
Blundell TL, Lapatto R, Wilderspin AF, Hemmings AM, Hobart PM, Danley DE, Whittle PJ. Blundell TL, et al. Trends Biochem Sci. 1990 Nov;15(11):425-30. doi: 10.1016/0968-0004(90)90280-o. Trends Biochem Sci. 1990. PMID: 2278102 Review.
Synergistic binding of inhibitors to the protease from HIV type 1.
Asante-Appiah E, Chan WW. Asante-Appiah E, et al. Biochem J. 1996 Apr 1;315 ( Pt 1)(Pt 1):113-7. doi: 10.1042/bj3150113. Biochem J. 1996. PMID: 8670094 Free PMC article.

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, et al. Vacca JP, et al. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4096-100. doi: 10.1073/pnas.91.9.4096. Proc Natl Acad Sci U S A. 1994. PMID: 8171040 Free PMC article.